"The Master Services Agreement may be terminated by either party upon the occurrence of certain events as set forth in the agreement, including material breach.
Amylin may terminate the Project Agreement, without cause, upon 60 days prior written notice to Ventiv, subject to certain early termination fees if Amylin terminates the Project Agreement prior to the first anniversary of deployment of the Ventiv sales representatives."
So ..... Amylin has an ongoing Master Agreement with Ventiv under which Ventive sells Amylin's products. It has provisions for termination by either Amylin or Ventive in the event that either party feels that it is not in their interests to continue the arrangement.
But now we have a new sub-agreement entitled the Project Agreement. One assumes that it is intended primarilty to cover sales of Bydureon in the US.
But Amylin deemed it necessary to include additional provisions - allowing Amylin to cancel the Project Agreement for reasons which were not covered by the cancellation provisions in the Master Agreement.
One wonders what additional problems Amylin envisages may occur with selling Bydureon in the US.
Maybe not. Do all pharma want additional sales force?(or a contract sales force). Perhaps this is prudent anticipation or was already discussed with interested parties. We will never know, but why spin?